An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Drug makers reported that Eli Lilly’s new pill called Foundayo, taken by mouth for people with type 2 diabetes, did better than the current oral pill semaglutide in a late-stage clinical trial. The headline means Foundayo lowered blood sugar measures more than the competitor did in the study that tests how well treatments work before regulators decide on approval. Foundayo is an oral GLP-1 receptor agonist. That’s a mouthful, but it helps to break it down: GLP-1 is a natural hormone made in the gut after you eat that tells your body to release insulin (which lowers blood sugar), slows stomach emptying, and can reduce appetite. A “receptor agonist” is a drug that mimics that hormone and activates the same signals. Semaglutide is a well-known example of this kind of drug; it’s sold as injectable brands like Ozempic and as an existing oral pill. Foundayo is another drug in the same family designed to be taken by mouth. What the study actually showed was a comparison in a Phase 3 trial — the large, late-stage kind of trial companies run to prove a drug works — where Foundayo produced a greater reduction in the main blood-sugar measure (usually A1c) than oral semaglutide. Phase 3 means the results are from a relatively large group of people, but the press line alone doesn’t give exact numbers, side-by-side details, how long the study lasted, or how the two drugs compared on weight change or side effects. The key point is that, in this trial, Foundayo outperformed oral semaglutide on the primary measure used to judge diabetes control. Why it matters is straightforward: more effective oral options would be useful for people with type 2 diabetes who prefer a pill to injections or who haven’t reached their blood sugar goals. Oral GLP-1 drugs are attractive because they combine the diabetes benefits of this hormone-mimicking approach with the convenience of a tablet. If Foundayo really offers stronger blood sugar control and is safe, it could become another option doctors consider when tailoring treatment. Caveats and risks are important. Company press and headlines can overstate findings; the snippet doesn’t show detailed data, independent peer review, or long-term safety information. GLP-1 drugs can cause side effects such as nausea, digestive upset, and in rare cases more serious issues. We don’t know from this snippet whether Foundayo’s side-effect profile is better, worse, or the same as oral semaglutide’s. Also, final approval by regulators and broader real-world experience are still needed before we can say it’s a better choice for everyone. Bottom line: Lilly says their new oral GLP-1 pill lowered blood sugar more than the current oral semaglutide in a big trial, which is promising, but we need full data and safety information to know how meaningful that advantage really is.
Source: BioPharm International